Clever Culture Systems Limited (ASX:CC5)
Australia · Delayed Price · Currency is AUD | Market Cap | 52.25M +111.4% |
| Revenue (ttm) | 5.17M +53.6% |
| Net Income | -744.00K |
| EPS | -0.00 |
| Shares Out | 2.18B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 389,986 |
| Average Volume | 786,333 |
| Open | 0.0220 |
| Previous Close | 0.0240 |
| Day's Range | 0.0220 - 0.0230 |
| 52-Week Range | 0.0140 - 0.0370 |
| Beta | 1.78 |
| RSI | 45.92 |
| Earnings Date | May 1, 2026 |
About Clever Culture Systems
Clever Culture Systems Limited engages in the research, development, and commercialization of technology solutions for medical industry in Australia, the United States, Sweden, the United Kingdom, China, Netherlands, and Germany. The company offers Automated Plate Assessment System, a solution that automates the imaging, analysis, and interpretation of microbiology culture plates primarily for microbiology laboratories and pharmaceutical manufacturing sector; Digital Microbiology; and APAS modules, an artificial intelligence algorithm that work... [Read more]
Financial Performance
Financial StatementsNews
Clever Culture Systems Earnings Call Transcript: Q3 2026
Partnerships and sales in the global pharma segment drove recurring revenue, with strong cash management and no supply chain disruptions. Two top 20 pharma customers are expected to be added soon, supporting a multi-year growth strategy.
Clever Culture Systems Transcript: AGM 2025
The meeting highlighted a return to profitability, major new contracts, and a strengthened balance sheet. Strategic initiatives included expanding the APAS platform and exploring new product development, with a focus on disciplined execution and shareholder value.
Clever Culture Systems Earnings Call Transcript: Q4 2025
Fiscal 2025 saw a breakthrough with APAS Independence gaining traction among top-tier pharmaceutical customers, driving financial stability and a robust sales pipeline. Major upgrades and new customer evaluations position the company for further growth in the expanding automation market.
Clever Culture Systems Earnings Call Transcript: Q3 2025
Second consecutive quarter of cash flow positive operations, with a robust sales pipeline and key validations from major pharmaceutical partners. Outlook remains strong for fiscal 2025, supported by expanded marketing, ongoing technology validation, and favorable industry trends.
Clever Culture Systems Earnings Call Transcript: Q2 2025
Sales growth in 2024 was driven by major pharma clients, with AstraZeneca validating and rolling out APAS technology. Cash flows are expected to remain break-even or better, supported by strong gross margins and a growing sales pipeline.
Clever Culture Systems Transcript: AGM 2024
The meeting highlighted a successful strategic pivot to pharmaceutical environmental monitoring, strong financial progress with new capital and major sales, and a restructured board. Key resolutions included director elections, incentive plans, and a company name change, with all votes conducted by poll.
Clever Culture Systems Earnings Call Transcript: Q1 2025
Record sales and major contracts with AstraZeneca and BMS drove strong commercial momentum and positive cash flow outlook. Over AUD 4.4 million in committed inflows support expectations for positive net operating and investing cash flows in the next two quarters.
Clever Culture Systems Earnings Call Transcript: Q4 2024
Strong sales momentum with major pharmaceutical clients, highlighted by a significant AstraZeneca contract and record instrument shipments expected in H1 FY2025. Cash position remains stable, with further inflows anticipated and expanded market engagement underway.